Latest Biotech News

Revolution Medicines’ pan-RAS inhibitor daraxonrasib delivered a major survival benefit in its Phase 3 RASolute 302 trial for metastatic pancreatic ductal adenocarcinoma, beating standard...

UCB agreed to acquire Neurona Therapeutics for up to $1.2 billion, betting that a seizure cell-therapy platform can broaden its largely small-molecule epilepsy portfolio. UCB said the acquisition...

Roche announced it will initiate another global Phase 3 trial for Duchenne muscular dystrophy gene therapy Elevidys, aiming to generate data that could support an updated European...

Eli Lilly reported positive top-line results from a cardiovascular outcomes trial of Foundayo (orforglipron), meeting the study’s heart safety objective versus insulin glargine in adults with type...

Two separate policy signals emerged from FDA-facing coverage: the agency is moving toward easing restrictions on certain compounded peptides while also setting out a policy agenda that would make...

Storm Therapeutics closed a $56 million Series C to advance STC-15, its METTL3-targeting RNA enzyme inhibitor, through Phase 2 development in sarcoma. The company said the financing will support...

Neomorph secured a $100 million Series B financing round to advance NEO-811, an oral molecular glue degrader targeting ARNT (HIF-1β), through its Phase I/II trial in clear cell renal cell...

University of Cambridge-led researchers reported a targeted gene-delivery approach that calms lung inflammation during respiratory infection in mouse models by locally expressing immunomodulatory...

Alamar Biosciences began trading on Nasdaq after pricing its initial public offering of 12.94 million shares at $17 each, raising gross proceeds of about $220 million for its Argo HT platform and...

Kailera Therapeutics priced a record-setting upsized IPO, raising $625 million gross to fund late-stage development of its injectable and oral obesity pipeline, including ribupatide (KAI-9531)...

Kailera Therapeutics priced an upsized IPO that raised $625 million to fund its obesity pipeline, following earlier Series A/B rounds. The offering sets a new benchmark for US biopharma IPOs as...

Roche’s Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million, aiming to expand its cancer molecular residual disease (MRD) diagnostics portfolio. The deal adds Saga’s...

Roche announced a new global Phase 3 trial for Elevidys (delandistrogene moxeparvovec), seeking a path toward European approval after a negative European Medicines Agency review. The study is...

UCB agreed to buy Neurona for up to $1.2 billion, adding seizure cell therapy ambitions to its predominantly small-molecule neurology portfolio. UCB said the acquisition is intended to diversify...

FDA’s Office of Prescription Drug Promotion (OPDP) enforcement is intensifying, reshaping what pharma can say and show in promotional materials. A compliance analysis described a rapid expansion...

Takara Bio and Resistomap strengthened their partnership to develop high-throughput antimicrobial resistance (AMR) surveillance products from environmental samples. The SmartChip Biosecurity...

Delta-Fly Pharma said it is pursuing an NDA path for radgocitabine (DFP-10917) after a Phase 3 AML trial missed its primary endpoint. The company plans to discuss with the FDA using earlier-stage...

Revolution Medicines’ daraxonrasib won a major Phase 3 survival signal in metastatic pancreatic cancer, driving deal and pipeline attention around its RAS-targeting approach. The company reported...

BioSpace tallies showed biopharma layoffs slowed year over year in Q1 2026, but total affected employees rose. The reported jump was driven largely by Viatris planning to cut up to 10% of its...

Transformative Biotech said it has developed extraction-free PCR chemistry for point-of-care testing, removing the bottleneck of nucleic acid extraction from sample workflows. The company’s...